Allena Pharmaceuticals Quick Ratio (ALNA) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Allena Pharmaceuticals Inc.  (NASDAQ: ALNA)

Allena Pharmaceuticals's Quick Ratio

ALNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2022, Quick Ratio fell to 0.66 a new company low.

Within Biotechnology & Pharmaceuticals industry 182 other companies have achieved higher Quick Ratio than Allena Pharmaceuticals in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 2655 to 3073.

Explain Quick Ratio?
How much Cash & cash equivalents ALNA´s has?
What are ALNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALNA Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change 33.99 % 48.71 % 163.45 % 96.51 % 16.29 %
Y / Y Cash & cash equivalent Change -75.28 % -75.49 % -14.42 % 34.13 % 0.77 %
Quick Ratio MRQ 0.66 0.92 1.95 5.48 3.56
ALNA's Total Ranking # 3073 # 2655 # 1780 # 920 # 1280
Seq. Current Liabilities Change 3.96 % -37.1 % 108.35 % -1.65 % 15.39 %
Seq. Cash & cash equivalent Change -25.92 % -70.34 % -25.81 % 51.64 % -26.54 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 183
Healthcare Sector # 999
Overall Market # 3073


Quick Ratio Statistics
High Average Low
39.66 8.47 0.66
(Sep 30 2018)   (Jun 30 2022)




Financial Statements
Allena Pharmaceuticals's Current Liabilities $ 10 Millions Visit ALNA's Balance sheet
Allena Pharmaceuticals's Cash & cash equivalent $ 7 Millions Visit ALNA's Balance sheet
Source of ALNA's Sales Visit ALNA's Sales by Geography


Cumulative Allena Pharmaceuticals's Quick Ratio

ALNA's Quick Ratio for the trailling 12 Months

ALNA Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 80.01 % 77.09 % 55.47 % -3.57 % -31.48 %
Y / Y Cash & cash equivalent TTM Growth -32.96 % -17.17 % 4.24 % 12.62 % -3.07 %
Quick Ratio TTM 2.02 2.66 3.63 5.09 5.43
Total Ranking TTM # 5385 # 1276 # 5029 # 5121 # 5103
Seq. Current Liabilities TTM Growth 6.39 % 8.62 % 35.04 % 15.36 % 4.66 %
Seq. Cash & cash equivalent TTM Growth -18.94 % -20.54 % -3.65 % 8.03 % 0.16 %

Quick ratio ranking by company, industry and sector >> Back to ALNA Financial Strength Comparisons >> Go to Compare ALNA Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2022 to $10.05 millions, cumulative Quick Ratio decreased to 2.02 below the Allena Pharmaceuticals Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 194 other companies have achieved higher Quick Ratio than Allena Pharmaceuticals. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 1276 to 5385.

Explain Quick Ratio?
How much Cash & cash equivalents ALNA´s has?
What are ALNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 195
Healthcare Sector # 1187
Within the Market # 5385


trailing twelve months Quick Ratio Statistics
High Average Low
14.71 6.66 1.96
(Sep 30 2018)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Champions Oncology Inc   1.74 $ 8.058  Millions$ 4.636  Millions
Mink Therapeutics Inc   1.71 $ 29.847  Millions$ 17.427  Millions
Eiger Biopharmaceuticals Inc   1.71 $ 36.572  Millions$ 21.411  Millions
Genfit S a   1.65 $ 72.549  Millions$ 44.094  Millions
Ladrx Corporation  1.61 $ 4.112  Millions$ 2.558  Millions
Pluri Inc   1.58 $ 10.779  Millions$ 6.829  Millions
Brainstorm Cell Therapeutics inc   1.56 $ 12.244  Millions$ 7.846  Millions
Taysha Gene Therapies Inc   1.54 $ 66.239  Millions$ 42.953  Millions
Aerie Pharmaceuticals Inc   1.54 $ 184.372  Millions$ 119.662  Millions
Eloxx Pharmaceuticals Inc   1.54 $ 30.048  Millions$ 19.504  Millions
Agenus Inc  1.49 $ 238.330  Millions$ 159.723  Millions
Bio techne Corp  1.47 $ 247.029  Millions$ 168.083  Millions
Xtant Medical Holdings Inc   1.46 $ 16.495  Millions$ 11.317  Millions
Repligen Corp  1.45 $ 596.512  Millions$ 411.830  Millions
Outlook Therapeutics Inc   1.41 $ 26.021  Millions$ 18.430  Millions
Apeiron Capital Investment Corp   1.33 $ 0.558  Millions$ 0.421  Millions
Bluebird Bio Inc   1.32 $ 132.509  Millions$ 100.415  Millions
Mesoblast Limited  1.31 $ 60.447  Millions$ 46.002  Millions
Beam Therapeutics Inc   1.25 $ 265.623  Millions$ 212.278  Millions
Moderna Inc   1.16 $ 7,897.000  Millions$ 6,812.000  Millions
10x Capital Venture Acquisition Corp Iii  1.14 $ 0.491  Millions$ 0.429  Millions
Kiromic Biopharma Inc   1.09 $ 6.511  Millions$ 5.969  Millions
Meiragtx Holdings Plc  1.07 $ 72.108  Millions$ 67.505  Millions
Halozyme Therapeutics Inc   1.05 $ 209.360  Millions$ 199.512  Millions
Valneva Se  1.04 $ 324.162  Millions$ 310.679  Millions
Futuretech Ii Acquisition Corp   1.03 $ 0.332  Millions$ 0.322  Millions
Sab Biotherapeutics Inc   1.03 $ 16.616  Millions$ 16.137  Millions
Sorrento Therapeutics Inc   0.92 $ 133.604  Millions$ 145.321  Millions
Calidi Biotherapeutics Inc   0.88 $ 0.329  Millions$ 0.374  Millions
Tc Biopharm holdings Plc  0.81 $ 7.395  Millions$ 9.164  Millions

Date modified: 2026-08-29T17:38:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.